Publication Date
In 2025 | 1 |
Since 2024 | 1 |
Since 2021 (last 5 years) | 2 |
Since 2016 (last 10 years) | 2 |
Since 2006 (last 20 years) | 2 |
Descriptor
Behavior Problems | 2 |
Foreign Countries | 2 |
Intelligence Quotient | 2 |
Mild Intellectual Disability | 2 |
Addictive Behavior | 1 |
Adolescents | 1 |
Adults | 1 |
Age Differences | 1 |
At Risk Persons | 1 |
Attention Deficit… | 1 |
Autism | 1 |
More ▼ |
Author
Dinnissen, Mariken | 1 |
Eric Blaauw | 1 |
Hoekstra, Pieter J. | 1 |
Popma, Arne | 1 |
Reijnen, Sam | 1 |
Reurts, Eva Enneke | 1 |
Rianne Suelmann | 1 |
Troost, Pieter W. | 1 |
Publication Type
Journal Articles | 2 |
Reports - Research | 2 |
Education Level
Audience
Location
Netherlands | 2 |
Laws, Policies, & Programs
Assessments and Surveys
Wechsler Adult Intelligence… | 1 |
Wechsler Intelligence Scale… | 1 |
What Works Clearinghouse Rating
Rianne Suelmann; Eric Blaauw – Journal of Intellectual & Developmental Disability, 2025
Background: Addiction medicine still largely neglects the topic of mild and borderline intellectual disabilities (MBID), although patients with MBID are considered a risk group for substance-related problems and offending behaviour. This study aimed to explore the cognitive and adaptive impairments of inpatients in forensic addiction mental health…
Descriptors: Substance Abuse, Mild Intellectual Disability, At Risk Persons, Mental Health
Reurts, Eva Enneke; Troost, Pieter W.; Dinnissen, Mariken; Reijnen, Sam; Hoekstra, Pieter J.; Popma, Arne – Journal of Intellectual Disabilities, 2021
A retrospective chart study of patients on open-label aripiprazole treatment was conducted in the Netherlands to add to the knowledge of aripiprazole in children and young adults with mild and borderline intellectual disabilities (IDs). Fifty-three youths, mean age 14.7 ± 3.4 years and mean IQ 64.5 ±13.8, were included. Treatment responders were…
Descriptors: Mild Intellectual Disability, Drug Therapy, Outcomes of Treatment, Foreign Countries